An anti-mouse OX40/CD137 bispecific antibody showed greater anti-tumour activity than a combination of OX40 and CD137 agonists in a CT26 mouse tumour model, which was associated with peripheral T cell activation and proliferation. This evidence concerns the gene TNFRSF4 and neoplasm.